TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of S-1 in Combination With Radiotherapy in Esophageal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Joined the study voluntarily and signed informed consent form;~* Age \>75 or age 18-75 who are intolerant of or reject intravenous chemotherapy~* Both genders~* Esophageal squamous cell carcinoma confirmed by pathology~* Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a, AJCC 6th)~* No radiotherapy, chemotherapy or other treatments prior to enrollment~* PS ECOG 0-2~* Life expectancy of more than 3 months~* Hemoglobin（Hb）≥9 g/dL~* WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L~* platelet count (Pt) ≥100x 109/L~* Hepatic function: ALAT and ASAT \< 2.5 x ULN, TBIL\<1.5 x ULN~* Renal function: creatinine \< 1.5 x ULN~* No immuno-deficiency~* Use of an effective contraceptive for adults to prevent pregnancy.~Exclusion Criteria:~* Complete esophageal obstruction~* Deep esophageal ulcer~* Esophageal perforation~* Haematemesis~* After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting therapy~* Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years~* Participation in other interventional clinical trials within 30 days~* Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives~* Drug addiction~* Alcoholism or AIDS~* Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior~* Patient who has metastasis such as lung, liver metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1 (Type: EXPERIMENTAL): Patients will receive chemoradiation with S-1.~Interventions:~Drug: S-1 Radiation: Radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women not of childbearing potential (WNOCBP) and males. Women must have documented proof they are not of childbearing potential~* BMI of 20.0 to 38.0 kg/m2, inclusive~* Hepatic subjects classified as Child-Pugh mild (Class A) or Child-Pugh moderate (Class B) who have had no significant change to disease status in past 6 months and are on stable treatment regimen~* Healthy subjects must not have clinically significant deviations from normal in medical history, physical exam, ECGs, vital signs or clinical lab values~Exclusion Criteria:~* Evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation~* Use of corticosteroids, nonsteroidal anti-inflammatory compounds, aspirin or other antiplatelet agents or anticoagulants within 2 weeks of dosing~* Healthy subjects must not have used tobacco or have a history of drug or alcohol abuse within the last 6 months~* Subjects must not have a current or recent (within 3 months) GI disease that increases participant risk of GI bleeding or interferes with absorption of the study drug~Other protocol defined inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Mild Hepatic Subjects (Type: EXPERIMENTAL): Subjects are given a single dose of BMS-986177
- Moderate Hepatic Subjects (Type: EXPERIMENTAL): Subjects are given a single dose of BMS-986177
- Healthy Match Subjects (Type: EXPERIMENTAL): Subjects are given a single dose of BMS-986177

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fibrocaps in Liver Surgery in the Netherlands

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥ 18 years of age~2. Subjects who are able and willing to provide written and signed informed consent~3. Willing to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits~4. Has a life expectancy of at least one year~5. Presence of mild or moderate bleeding/oozing and control by conventional surgical techniques including but not limited to suture, ligature, and cautery is ineffective or impractical~Exclusion Criteria:~1. Pregnant or lactating women~2. Has a known intolerance to blood products or to Fibrocaps components~3. Unwilling to receive human blood products~4. Subject has a known allergy to porcine gelatin~5. Has a mental or physical condition that would, in the opinion of the Investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol~6. Currently participating or has participated in another clinical study involving another investigational agent within 4 weeks of the planned date of surgery, or is planning participation in another clinical trial during the 4 weeks after surgery~7. Has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the Investigator~8. Platelets(PLT) \< 100 x109 PLT/L during screening~9. Activated Partial Thromboplastin Time (aPTT) \> 100 seconds during screening~10. International Normalized Ratio (INR) \> 2.5 during screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fibrocaps + Gelatin sponge (Type: EXPERIMENTAL): Topical Fibrocaps powder followed by application of gelatin sponge
- Gelatin Sponge (Type: ACTIVE_COMPARATOR): approved device for surgical bleeding

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Rhinitis, Rhinoconjunctivitis, Positive Rast result to grass pollen, Positive skin prick test to grass pollen, Positive specific provocation to grass pollen,~Exclusion Criteria:~Serious chronic diseases, Other perennial allergies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was given the same way as a sublingual preparation.
- Liquid formulation of an extract of a 6 grass pollen mixture (Type: EXPERIMENTAL): Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 65 years, or age under 65 years, unable to tolerate high dose chemotherapy with autologous stem cell support~* Histologically confirmed mantle cell lymphoma, stage II-IV at time of diagnosis~* No previous treatment for lymphoma except radiotherapy or one cycle of any chemotherapy regimen for lymphoma~* WHO Performance Status 0-3~* Written informed concent~* Female subjects of childbearing potential must agree to use and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, through study drug therapy and for 4 weeks after the end of study drug therapy~* Male subjects must agree to use condoms throughout study drug therapy if their partner is of childbearing potential, and has no contraception, and agree to not donate semen during study drug therapy and for one week after end of study drug therapy~* All subjects must agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation, and agree not to share study medication with another person~Exclusion Criteria:~* Impaired liver function~* ANC less than 1.0 x 10 9, unless caused by bone marrow infiltration by lymphoma~* Platelet count less than 60 x 10 9, unless caused by bone marrow infiltration by lymphoma~* Creatinine clearance below 50 ml/min (cockcroft formula))~* Known HIV positivity~* Known seropositivity for HCV, HBsAG, anti-HBc, or other active infection uncontrolled by treatment~* Psychiatric illness or condition which could interfere with the subject´s ability to understand the requirements of the study~* Requirement of corticosteroid therapy at a dose over 10 mg prednisolone/day~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lenalidomide, bendamustine, rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Precision Treatment With Angiotensin Converting Enzyme Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women over 20 years of age and less than 79 years of age~* Hypertension~* No history of ACEI use~Exclusion Criteria:~* Acute coronary syndrome, cerebrovascular accident, symptomatic peripheral artery disease, or coronary revascularization in the past three months~* Decompensated heart failure~* Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg~* Hemoglobin A1c \>9.0%~* Thyroid dysfunction~* Serum transaminase \>2 times the upper limit of normal levels~* Serum creatinine \>2.0 mg/dL~* Cancer~* Pregnant or breast-feeding women, and women of childbearing potential~* Patients who refused to participate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): This group will perform genetic study for predicting adverse reaction to ACEI. Based on the result of genetic study, participants will receive ACEI or ARB.
- Control (Type: ACTIVE_COMPARATOR): Participants will receive ACEI without genetic study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~COHORT 1: HIV seronegative~1. Older than 18 years;~2. HSV-2 seropositive by Western Blot;~3. not receiving any drugs with known anti-HSV-2 activity for study duration;~4. women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;~5. women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;~6. in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;~7. planning to remain resident in the area of the study center for the duration of the study participation;~8. HIV seronegative~COHORT 2: HIV seropositive~1. Older than18 years;~2. HSV-2 seropositive by Western Blot;~3. not receiving any drugs with known anti-HSV-2 activity for study duration;~4. women of child bearing potential who are sexually active with men must be using a medically accepted method of contraception as judged by the investigator;~5. women of child-bearing potential must have a negative pregnancy test (urine) at screening visit;~6. in general good health, without other serious medical conditions and specifically with normal renal and hepatic function, as determined by the patient's medical history;~7. planning to remain resident in the area of the study center for the duration of the study participation;~8. HIV seropositive~9. CD4 count over 250 cell/mm3~10. Not taking antiretroviral therapy~Exclusion Criteria:~For both cohorts:~1. hypersensitivity to acyclovir or valacyclovir;~2. pregnant women;~3. Taking immunosuppressive therapies, such as chronic oral steroids or immune modulatory drugs.~For cohort 2:~1. CD4 count\<250 cell/mm3~2. Taking antiretroviral therapy at the time of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 70 years patients needing methadone for their opioid dependence who are either naives of methadone treatment (prescribed) since at least 1 month~* need to switch from buprenorphine to methadone treatment~* negative test for pregnancy~Exclusion Criteria:~* co-dependent on alcohol and benzodiazepines,~* inmates,~* pregnant women,~* individual in irregular situation or who cannot be joined by phone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Methadone inducted by a primary care physician
- B (Type: ACTIVE_COMPARATOR): Methadone inducted (in CSAPA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Severe Acute Malnutrition in SCD, in Northern Nigeria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnoses of SCA, comparison children without SCD~* severe malnutrition defined as a BMI z-score \< -3~* age between 5 and 12 years (assessment can take place up until the 13th birthday)~* pass the appetite test~* uncomplicated malnutrition (good appetite, alert, no signs of infection of respiratory distress)~Exclusion Criteria:~* children with complicated severe acute malnutrition~* children with electrolyte disturbances (serum Na, K, PO4) at baseline~* children on disease-modifying therapy (hydroxyurea or regular blood transfusion therapy)~* children enrolled in other studies~* children with diabetes and other chronic illnesses~* children with known HIV infection~* children with a known allergy to dairy or peanuts.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- SCD - Ready-to-use therapeutic food and Hydroxyurea (Type: EXPERIMENTAL): 50-75 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive ready-to-use therapeutic food and hydroxyurea (20mg/kg/day)
- SCD - Ready-to-use therapeutic food alone (Type: PLACEBO_COMPARATOR): 50-75 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive ready-to-use therapeutic food alone
- Non-SCD siblings with severe malnutrition (Type: PLACEBO_COMPARATOR): To decrease the likelihood of sharing limited food resources, we will enroll up to 100 malnourished non-SCD siblings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examining Rehabilitation Training Methods

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of acute stroke~* admission to acute inpatient rehabilitation~* impairment in cognitive functions (as indicated by 14-item Executive Interview ≥ 3)~Exclusion Criteria:~* diagnosis of dementia in the medical record~* inability to follow two-step commands 80% of the time~* severe aphasia (score of 0 or 1 on the Boston Diagnostic Aphasia Examination 3rd Edition Severity Rating Scale)~* current untreated major depressive, bipolar, or psychotic disorder (PRIME-MD)~* drug or alcohol abuse within 3 months (Mini-International Neuropsychiatric Interview)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guided Training (Type: EXPERIMENTAL): Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence.
- Directed Training (Type: ACTIVE_COMPARATOR): Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Homozygous for the F508del-CFTR mutation; historical genotype must be documented in the participant's source documents.~* Percent predicted FEV1 \<40 of adjusted for age, sex, and height at Screening~Exclusion Criteria:~* Participant currently receiving invasive mechanical ventilation.~* History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant~* Any clinically significant laboratory abnormalities at screening that would interfere with the study assessments or pose an undue risk for the subject~* A 12-lead electrocardiograms (ECG) demonstrating QTcF \>450 msec at Screening~* History of solid organ or hematological transplantation~* History of alcohol or drug abuse in the past year~* Ongoing or prior participation in an investigational drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening.~* Use of strong inhibitors, moderate inducers, or strong inducers of CYP3A~* Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at Screening and Day 1.~* Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements~* Use of beta blockers or the equivalent at Screening.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumacaftor/Ivacaftor combination (Type: EXPERIMENTAL): Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete